UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

On the Discovery and Development of Pimavanserin: A Novel Drug Candidate for Parkinson’s Psychosis

Neurochemical research, 2014-10, Vol.39 (10), p.2008-2017

2014

Volltextzugriff (PDF)

ACP-103, a 5-hydroxytryptamine 2A receptor inverse agonist, improves the antipsychotic efficacy and side-effect profile of haloperidol and risperidone in experimental models

The Journal of pharmacology and experimental therapeutics, 2007-08, Vol.322 (2), p.862-870

2007

Volltextzugriff (PDF)

Discovery of a Potent, Orally Available, and Isoform-Selective Retinoic Acid β2 Receptor Agonist

Journal of medicinal chemistry, 2005-12, Vol.48 (24), p.7517-7519

2005

Volltextzugriff (PDF)

Constitutively Active Mutants of the Histamine H1 Receptor Suggest a Conserved Hydrophobic Asparagine-Cage That Constrains the Activation of Class A G Protein-Coupled Receptors

Molecular pharmacology, 2008-01, Vol.73 (1), p.94

2008

Volltextzugriff (PDF)

Identification of novel subtype selective RAR agonists

Biochemical pharmacology, 2005-12, Vol.71 (1), p.156-162

2005

Volltextzugriff (PDF)

Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2 mg/day, but does not enhance efficacy of haloperidol, 2 mg/day: Comparison with reference dose risperidone, 6 mg/day

Schizophrenia research, 2012-11, Vol.141 (2), p.144-152

2012

Volltextzugriff (PDF)

Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2mg/day, but does not enhance efficacy of haloperidol, 2mg/day: Comparison with reference dose risperidone, 6mg/day

Schizophrenia research, 2012-11, Vol.141 (2-3), p.144-152

2012

Volltextzugriff (PDF)

Pharmacological characterization of AC-90179 [2-(4-methoxyphenyl)-N-(4-methyl-benzyl)-N-(1-methyl-piperidin-4-yl)-acetamide hydrochloride]: a selective serotonin 2A receptor inverse agonist

The Journal of pharmacology and experimental therapeutics, 2004-09, Vol.310 (3), p.943-951

2004

Volltextzugriff (PDF)

Behavioral effects of clozapine, pimavanserin, and quetiapine in rodent models of Parkinson's disease and Parkinson's disease psychosis: evaluation of therapeutic ratios

Behavioural pharmacology, 2013-10, Vol.24 (7), p.628-632

2013

Volltextzugriff (PDF)

The 5-HT1A receptor selective ligands, (R)-8-OH-DPAT and (S)-UH-301, differentially affect the activity of midbrain dopamine neurons

Naunyn-Schmiedeberg's archives of pharmacology, 1993-04, Vol.347 (4), p.353-362

1993

Volltextzugriff (PDF)

Discovery of an Ectopic Activation Site on the M 1 Muscarinic Receptor

Molecular pharmacology, 2002-06, Vol.61 (6), p.1297-1302

2002

Volltextzugriff (PDF)

II. In vitro evidence that (−)-OSU6162 and (+)-OSU6162 produce their behavioral effects through 5-HT2A serotonin and D2 dopamine receptors

JOURNAL OF NEURAL TRANSMISSION, 2011-11, Vol.118 (11), p.1523-1533

2011

Volltextzugriff (PDF)

Design, Synthesis, and Structure−Activity Analysis of Isoform-Selective Retinoic Acid Receptor β Ligands

Journal of medicinal chemistry, 2009-03, Vol.52 (6), p.1540-1545

2009

Volltextzugriff (PDF)

Characterization of the Binding Site of the Histamine H3 Receptor. 1. Various Approaches to the Synthesis of 2-(1H-Imidazol-4-yl)cyclopropylamine and Histaminergic Activity of (1R,2R)- and (1S,2S)-2-(1H-Imidazol-4-yl)- cyclopropylamine

Journal of medicinal chemistry, 1999-04, Vol.42 (7), p.1115-1122

1999

Volltextzugriff (PDF)

1 The Chemistry and Biochemistry of C-Nucleosides and C-Arylglycosides

Progress in Medicinal Chemistry, 1985, Vol.22, p.1-65

1985

Volltextzugriff (PDF)

Constitutively Active Mutants of the Histamine H 1 Receptor Suggest a Conserved Hydrophobic Asparagine-Cage That Constrains the Activation of Class A G Protein-Coupled Receptors

Molecular pharmacology, 2008-01, Vol.73 (1), p.94-103

2008

Volltextzugriff (PDF)

8-Hydroxy-2-(dipropylamino)tetralin, a new centrally acting 5-hydroxytryptamine receptor agonist

Journal of medicinal chemistry, 1981-08, Vol.24 (8), p.921-923

1981

Volltextzugriff (PDF)

PET analysis of the 5-HT2A receptor inverse agonist ACP-103 in human brain

The international journal of neuropsychopharmacology, 2008-03, Vol.11 (2), p.163-171

2008

Volltextzugriff (PDF)

3-Heteroaryl-Substituted Quinuclidin-3-ol and Quinuclidin-2-ene Derivatives as Muscarinic Antagonists. Synthesis and Structure-Activity Relationships

Journal of medicinal chemistry, 1995-02, Vol.38 (3), p.473-487

1995

Volltextzugriff (PDF)

Isochromanone-based urotensin-II receptor agonists

Bioorganic & medicinal chemistry, 2005-04, Vol.13 (8), p.3057-3068

2005

Volltextzugriff (PDF)

Novel and potent small-molecule urotensin II receptor agonists

Bioorganic & medicinal chemistry, 2009-07, Vol.17 (13), p.4657-4665

2009

Volltextzugriff (PDF)

Synthesis of 1,2,4-Oxadiazole-, 1,3,4-Oxadiazole-, and 1,2,4-Triazole-Derived Dipeptidomimetics

Journal of organic chemistry, 1995-05, Vol.60 (10), p.3112-3120

1995

Volltextzugriff (PDF)

(R)- and (S)-8-acetyl-2-(dipropylamino)tetralin (LY-41) : two novel 5-HT1A receptor agonists

European journal of pharmacology, 1993-01, Vol.231 (1), p.69-76

1993

Volltextzugriff (PDF)

Discovery of the First Nonpeptide Agonist of the GPR14/Urotensin-II Receptor: 3-(4-Chlorophenyl)-3-(2- (dimethylamino)ethyl)isochroman-1-one (AC-7954)

Journal of medicinal chemistry, 2002-11, Vol.45 (23), p.4950-4953

2002

Volltextzugriff (PDF)

Binding-site modeling of the muscarinic m1 receptor: a combination of homology-based and indirect approaches

Journal of medicinal chemistry, 1993-04, Vol.36 (8), p.967-976

1993

Volltextzugriff (PDF)

1 – 25 von 144

Suche als RSS-Feed

Aktive Filter

KollektionNUS Single-Journal Subscriptions

ThemaOrganic Chemistry

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(137)
Mit Volltextzugriff
(121)

Publikationsform

Artikel
(142)
Buchkapitel
(2)

Sprache

Englisch
(144)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(76)
Life Sciences & Biomedicine
(67)
Animals
(60)
Pharmacology & Pharmacy
(54)
Biological And Medical Sciences
(42)
Rats
(42)
Medical Sciences
(40)
Pharmacology. Drug Treatments
(39)
Male
(35)
Neuropharmacology
(34)
Chemistry, Medicinal
(33)
Neurotransmitters. Neurotransmission. Receptors
(31)
Structure-Activity Relationship
(27)
Chemistry
(26)
Humans
(25)
Stereoisomerism
(24)
Physical Sciences
(22)
Chemistry, Organic
(18)
5-Ht
(16)
Tetrahydronaphthalenes - Pharmacology
(16)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

On the Discovery and Development of Pimavanserin: A Novel Drug Candidate for Parkinson’s Psychosis

ACP-103, a 5-hydroxytryptamine 2A receptor inverse agonist, improves the antipsychotic efficacy and side-effect profile of haloperidol and risperidone in experimental models

Discovery of a Potent, Orally Available, and Isoform-Selective Retinoic Acid β2 Receptor Agonist

Constitutively Active Mutants of the Histamine H1 Receptor Suggest a Conserved Hydrophobic Asparagine-Cage That Constrains the Activation of Class A G Protein-Coupled Receptors

Identification of novel subtype selective RAR agonists

Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2 mg/day, but does not enhance efficacy of haloperidol, 2 mg/day: Comparison with reference dose risperidone, 6 mg/day

Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2mg/day, but does not enhance efficacy of haloperidol, 2mg/day: Comparison with reference dose risperidone, 6mg/day

Pharmacological characterization of AC-90179 [2-(4-methoxyphenyl)-N-(4-methyl-benzyl)-N-(1-methyl-piperidin-4-yl)-acetamide hydrochloride]: a selective serotonin 2A receptor inverse agonist

Behavioral effects of clozapine, pimavanserin, and quetiapine in rodent models of Parkinson's disease and Parkinson's disease psychosis: evaluation of therapeutic ratios

The 5-HT1A receptor selective ligands, (R)-8-OH-DPAT and (S)-UH-301, differentially affect the activity of midbrain dopamine neurons

Discovery of an Ectopic Activation Site on the M 1 Muscarinic Receptor

II. In vitro evidence that (−)-OSU6162 and (+)-OSU6162 produce their behavioral effects through 5-HT2A serotonin and D2 dopamine receptors

Design, Synthesis, and Structure−Activity Analysis of Isoform-Selective Retinoic Acid Receptor β Ligands

Characterization of the Binding Site of the Histamine H3 Receptor. 1. Various Approaches to the Synthesis of 2-(1H-Imidazol-4-yl)cyclopropylamine and Histaminergic Activity of (1R,2R)- and (1S,2S)-2-(1H-Imidazol-4-yl)- cyclopropylamine

1 The Chemistry and Biochemistry of C-Nucleosides and C-Arylglycosides

Constitutively Active Mutants of the Histamine H 1 Receptor Suggest a Conserved Hydrophobic Asparagine-Cage That Constrains the Activation of Class A G Protein-Coupled Receptors

8-Hydroxy-2-(dipropylamino)tetralin, a new centrally acting 5-hydroxytryptamine receptor agonist

PET analysis of the 5-HT2A receptor inverse agonist ACP-103 in human brain

3-Heteroaryl-Substituted Quinuclidin-3-ol and Quinuclidin-2-ene Derivatives as Muscarinic Antagonists. Synthesis and Structure-Activity Relationships

Isochromanone-based urotensin-II receptor agonists

Novel and potent small-molecule urotensin II receptor agonists

Synthesis of 1,2,4-Oxadiazole-, 1,3,4-Oxadiazole-, and 1,2,4-Triazole-Derived Dipeptidomimetics

(R)- and (S)-8-acetyl-2-(dipropylamino)tetralin (LY-41) : two novel 5-HT1A receptor agonists

Discovery of the First Nonpeptide Agonist of the GPR14/Urotensin-II Receptor: 3-(4-Chlorophenyl)-3-(2- (dimethylamino)ethyl)isochroman-1-one (AC-7954)

Binding-site modeling of the muscarinic m1 receptor: a combination of homology-based and indirect approaches

Aktive Filter

Suchergebnisse filtern